Revance Therapeutics Inc (NASDAQ: RVNC) kicked off on Friday, down -4.50% from the previous trading day, before settling in for the closing price of $3.78. Over the past 52 weeks, RVNC has traded in a range of $2.30-$9.74.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 815.27% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 40.79%. With a float of $95.70 million, this company’s outstanding shares have now reached $104.90 million.
In an organization with 597 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 70.66%, operating margin of -67.21%, and the pretax margin is -72.59%.
Revance Therapeutics Inc (RVNC) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Revance Therapeutics Inc is 8.77%, while institutional ownership is 79.62%. The most recent insider transaction that took place on Nov 18 ’24, was worth 16,296. In this transaction CMO & Global Therapeutics Lead of this company sold 3,908 shares at a rate of $4.17, taking the stock ownership to the 104,945 shares. Before that another transaction happened on Apr 16 ’24, when Company’s Chief Commercial Officer sold 2,392 for $3.80, making the entire transaction worth $9,096. This insider now owns 114,864 shares in total.
Revance Therapeutics Inc (RVNC) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.61 earnings per share (EPS), higher than consensus estimate (set at -0.92) by 0.31. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.3 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 40.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.60% during the next five years compared to 0.57% growth over the previous five years of trading.
Revance Therapeutics Inc (NASDAQ: RVNC) Trading Performance Indicators
Take a look at Revance Therapeutics Inc’s (RVNC) current performance indicators. Last quarter, stock had a quick ratio of 3.05. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.92, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach -0.76 in one year’s time.
Technical Analysis of Revance Therapeutics Inc (RVNC)
Let’s dig in a bit further. During the last 5-days, its volume was 1.97 million. That was inferior than the volume of 2.73 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 31.61%. Additionally, its Average True Range was 0.33.
During the past 100 days, Revance Therapeutics Inc’s (RVNC) raw stochastic average was set at 21.95%, which indicates a significant decrease from 24.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 99.69% in the past 14 days, which was lower than the 148.46% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.96, while its 200-day Moving Average is $4.56. However, in the short run, Revance Therapeutics Inc’s stock first resistance to watch stands at $3.76. Second resistance stands at $3.92. The third major resistance level sits at $3.99. If the price goes on to break the first support level at $3.53, it is likely to go to the next support level at $3.46. The third support level lies at $3.30 if the price breaches the second support level.
Revance Therapeutics Inc (NASDAQ: RVNC) Key Stats
The company with the Market Capitalisation of 361.67 million has total of 104,902K Shares Outstanding. Its annual sales at the moment are 234,040 K in contrast with the sum of -323,990 K annual income. Company’s last quarter sales were recorded 59,880 K and last quarter income was -38,120 K.
